원저 : 만성 골수성 백혈병에서 인터페론 및 화학요법의 병용과 화학요법 단독에 의한 치료효과

Interferon`s ability to reduce the self-renewal capacity of leukemic Stem cells as well as the exgression of oncogens and to increase natural kilier cell cytotoxicity promptoly made ue study it`s synergistic therapeutic efficacy with chemotherapy on patients with chronic myelocytic leukemia, 29 patients with philadephia ehromos6me positivity had begun the study with protocol consisted with subcutaneous daily dose of 1 or 2 mega unit of interferon alpha and chemotherapy. Among them, 21 were on chronic phase, 8 on ndvaneed disease. 12 patients of chronic phase have had hematological complete response (57.1% ) and 4 of advanced diseases returned to chronic phase again. Also we had selected another 25 patients who have had chemotherapy only as a controls far comparison. Among 25 of them, 22 were on chronic phase, only 3 could enjoy hematological complete response (13,6%). 3 on advanced disease had no response with chemotherapy alone. There has been a significant slowing of the leukocyte doubling time and reduction of the hydroxyurea requirement in interferon responded patients A few (25 %) of them had psrtia1 cytogenetic remission in their bone marrow and peripheral blood. Even if our date is still in immature because of the short period of observation, it give us a speculation that our protocal of combi0ed modality might be another new thereapeutic option for patients with chronic myelocytic leukemia.